Gleevec/Glivec

NICE backs BMS leukaemia drug Sprycel

to 66% of patients taking Novartis' Gleevec (imatinib), the current standard care. ... With a list price of £30, 000 per patient per year, Sprycel was originally rejected due to its lack of cost-effectiveness, and NICE approved the cheaper Gleevec.

Novartis says its biosimilar sales should reach $1bn this year

The biosimilar franchise helped Novartis shrug off a second quarter of generic competition for its cancer drug Gleevec in the US, a lacklustre performance from its Alcon eyecare division and less

New drugs help Novartis shrug off Gleevec competition

Novartis has managed to maintain sales in the second quarter of the year, despite facing the first full quarter of generic competition to cancer blockbuster Gleevec in the US. ... Sales of chronic myeloid leukaemia drug Gleevec (imatinib) fell by a

As promised, Novartis' Entresto is a 'slow burner'

Cosentyx was however a high point in a quarter undermined by generic competition to Novartis' cancer drug Glivec/Gleevec (imatinib) - with sales down 22% to $835m - and underperformance by eye health

Roche boosts cancer portfolio with $1bn Blueprint deal

of Novartis' big-selling kinase inhibitor Gleevec/Glivec (imatinib), a leukaemia therapy.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]